CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-01 | LEONARD JOHN M President and CEO | Grant or award | +113,586 | 960,072 | ||
| 2024-03-01 | LEONARD JOHN M President and CEO | Grant or award · Stock Option (right to buy) | +163,929 | 163,929 | ||
| 2024-01-08 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale 10b5-1 | −1,608 | $28.66 | $46K | 44,594 |
| 2024-01-08 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale 10b5-1 | −667 | $29.38 | $20K | 43,927 |
| 2024-01-03 | LEONARD JOHN M President and CEO | Sale | −19,223 | $29.46 | $566K | 846,486 |
| 2024-01-03 | Lebwohl David EVP, Chief Medical Officer | Sale | −5,843 | $29.46 | $172K | 54,372 |
| 2024-01-03 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −5,532 | $29.46 | $163K | 46,202 |
| 2024-01-03 | Goddard Glenn EVP, Chief Financial Officer | Sale | −5,365 | $29.46 | $158K | 40,585 |
| 2024-01-03 | Hicks Derek EVP, Chief Business Officer | Sale | −3,877 | $29.46 | $114K | 36,987 |
| 2024-01-03 | BASTA JAMES EVP, General Counsel | Sale | −3,805 | $29.46 | $112K | 51,474 |
| 2024-01-03 | Clark Eliana EVP, Chief Technical Officer | Sale | −307 | $30.12 | $9K | 45,146 |
| 2024-01-03 | Clark Eliana EVP, Chief Technical Officer | Sale | −4,301 | $29.46 | $127K | 40,845 |
| 2024-01-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise | +3,500 | 51,734 | ||
| 2024-01-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise · Restricted Stock Unit | −3,500 | 3,500 | ||
| 2024-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise | +3,187 | 60,215 | ||
| 2024-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise · Restricted Stock Unit | −3,187 | 3,189 | ||
| 2024-01-01 | LEONARD JOHN M President and CEO | Option exercise | +7,848 | 865,709 | ||
| 2024-01-01 | LEONARD JOHN M President and CEO | Option exercise · Restricted Stock Unit | −7,848 | 7,850 | ||
| 2024-01-01 | Goddard Glenn EVP, Chief Financial Officer | Option exercise | +3,062 | 45,950 | ||
| 2024-01-01 | Goddard Glenn EVP, Chief Financial Officer | Option exercise · Restricted Stock Unit | −3,062 | 3,064 |
Page 8 of 40 · 783 trades